Vancouver, British Columbia – March 11, 2015 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) announces the successful development of a third innovative skin-lightening compound that has superior safety, with zero hydroquinone release and 8 times the efficacy of deoxyarbutin. This innovation was made possible through Sirona’s platform technology of fluorination chemistry and through support of the European Union and the European Regional Development Fund (E.R.D.F.).
Sirona Biochem has conducted comprehensive safety and efficacy studies in accordance with the standards of the cosmetic industry, demonstrating that SBM-TFC-1067 has the following scientifically proven properties:
- A superior safety profile over deoxyarbutin, with zero hydroquinone released in all chemical and biological tested conditions
- 8 times the efficacy of deoxyarbutin
- A high capacity to reach the site of action in the epidermis
- Additional antioxidant properties
“These results support our belief that we have developed the safest, most effective skin lightener in the world”, said Attila Hajdu. “We foresee partnering this asset within a year. Our preferred partner will be a multinational corporation with a commercial infrastructure in Japan and Asia-Pacific. The valuation of this partnership will reflect the exceptional attributes of SBM-TFC-1067.”
The global skin lightening market is expected to reach $20 Billion USD by 2018.
As previously announced, the detailed safety and efficacy data will be presented at the Bio-Europe conference in Paris on March 11th and will be available for download on our corporate website under the Events section.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information please visit www.sironabiochem.com.
About the Skin Lightening Project
Sirona Biochem’s French subsidiary TFChem received a $1.9 million grant in November 2011. This project is co-financed by the European Union and Europe Witnesses in Haute-Normandie with the support of the European Regional Development Fund (E.R.D.F.). A consortium of partners, including the University of Rouen (LMSM EA4312), contract research organization Biogalenys, and TFChem has been assembled to advance this project. The French government and EU are looking to promote and initiate collaborative projects that are focused on the development of new products and services containing a high level of innovation.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Sirona Biochem Corp.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.